Asymptomatic Long QT Syndrome When Initial Therapy Does Not Achieve the QTc Target
Clinical Scenario
This protocol addresses asymptomatic patients with congenital long QT syndrome and persistent QT interval prolongation — with or without a confirmed pathogenic mutation — who have not achieved the expected response to first-line management.
Previous Treatment — Failure Condition
First-line management consists of general measures (avoiding QT-prolonging drugs, correcting electrolyte abnormalities, avoiding genotype-specific arrhythmia triggers) plus a non-selective beta-blocker. In patients with an LQT3 (SCN5A) mutation, oral mexiletine is added.
Escalation trigger: First-line therapy is insufficient when the QTc interval does not shorten by 40 ms on oral mexiletine testing prior to initiating chronic treatment.
Next-Step Approach
In asymptomatic patients determined to have a high-risk profile by a validated LQTS risk calculator, a device-based intervention may be considered in addition to ongoing genotype-specific medical therapy. The complete risk-stratified criteria and full regimen are in the protocol.
References
DOI: 10.1093/eurheartj/ehac262
- Asymptomatic patient with or without pathogenic mutation and QT prolongation
- ICD implantation may be considered in asymptomatic LQTS patients with high-risk profile (according to the 1-2-3 LQTS Risk calculator) in addition to genotype-specific medical therapies (mexiletine in LQT3 patients).
View source ↗